BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//financecalendar.com - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:financecalendar.com
X-ORIGINAL-URL:https://www.financecalendar.com
X-WR-CALDESC:Events for financecalendar.com
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20280312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20281105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T070000
DTEND;TZID=America/New_York:20270202T080000
DTSTAMP:20261019T233328Z
CREATED:20261019T233328Z
LAST-MODIFIED:20261019T233328Z
UID:3014-1801551600-1801555200@www.financecalendar.com
SUMMARY:Eli Lilly (LLY) Earnings Q1 2027
DESCRIPTION:Next LLY Quarterly Earnings: Tuesday\, February 2\, 2027 at 7:00 am ET (12:00 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nEPS $7.02 vs $5.69 consensus\, revenue $17.60bn (Q3 2025)\nActual\nPending\n\nUpdated October 19\, 2026 \n\nEli Lilly and Company (NYSE: LLY) is expected to report its first-quarter 2027 financial results on Tuesday\, February 2\, 2027 at 7:00am ET (12:00pm London). The Indianapolis-based pharmaceutical group\, one of the world’s largest drugmakers by market value\, typically follows its earnings release with a conference call for analysts and investors. Markets watch this release closely because Eli Lilly’s weight-loss and diabetes drugs\, Zepbound and Mounjaro\, have become major drivers of both the company’s revenue and sentiment across the broader healthcare sector. Full schedule and background: Eli Lilly earnings calendar. \nBecause Eli Lilly has not yet confirmed its exact Q1 2027 reporting date at the time of writing\, this page uses an estimated date based on the company’s established pattern. Eli Lilly has historically reported fourth-quarter and full-year results in early February\, so a date near the start of the month is the reasonable working assumption rather than a confirmed fact. \nWhat is the Eli Lilly Q1 2027 earnings release?\nThis is Eli Lilly’s scheduled quarterly disclosure of financial performance\, covering revenue\, earnings per share (EPS\, the portion of profit allocated to each outstanding share)\, and guidance for the year ahead. The report is prepared under US securities law requirements and released via a press statement published on the company’s investor relations site\, followed by a live call where chief executive David Ricks and chief financial officer Lucas Montarce typically take questions from Wall Street analysts. Participants include sell-side analysts from major banks\, institutional investors\, and financial journalists who relay headline numbers to markets within seconds of release. \nEli Lilly’s quarterly results are watched well beyond the United States. The company’s drugs are sold and reimbursed across European health systems\, including the NHS in the United Kingdom\, and its manufacturing and supply decisions affect production sites in Ireland and continental Europe. Strong or weak results can move pharmaceutical shares in London\, Frankfurt and other European markets through sector-wide sentiment\, even though Eli Lilly itself is a US-listed company. \nWhen is the Eli Lilly earnings call and how to follow it\nThe results are expected to be released before the US market opens\, at 7:00am ET\, which is 12:00pm in London and early evening in parts of Asia. A conference call for investors and analysts usually follows shortly after the market open\, typically around 9:00am ET or 2:00pm London time\, though the exact call time is confirmed closer to the date. The release\, an accompanying slide presentation and a live audio webcast are normally made available on Eli Lilly’s investor relations website. Retail investors without access to institutional terminals can usually follow the webcast directly and read the transcript afterwards. \nWhat to expect\nAs of publication\, a consensus forecast for Eli Lilly’s Q1 2027 earnings per share and revenue has not yet been published. Analyst estimates typically firm up in the weeks immediately before the release\, once banks update their models following any pre-announcements\, conference presentations or regulatory news. When a consensus figure becomes available\, it is usually compiled from a poll of sell-side analysts by data providers such as LSEG or FactSet. \nAnalysts are likely to focus closely on sales volumes and pricing for Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes)\, since these two drugs have become the single biggest swing factor in Eli Lilly’s results. Other areas of focus typically include manufacturing capacity updates\, given persistent supply constraints on incretin-class drugs\, oncology and immunology pipeline progress\, and any changes to full-year guidance. Currency movements\, particularly a stronger dollar against the euro and pound\, can also affect reported international revenue even when underlying demand is unchanged. \nThe table below shows Eli Lilly’s most recently reported quarterly results\, sourced from the company’s investor relations disclosures\, to provide context ahead of the Q1 2027 release. \n\n\n\nQuarter\nRevenue\nEPS\nvs estimate\n\n\n\n\nQ3 2025\n$17.60 billion\n$7.02\nBeat consensus of $5.69\n\n\n\nOnly the most recently confirmed quarter is included here because earlier figures were not independently verifiable against the company’s own disclosures at the time of writing. Readers wanting the fuller run of historical results should consult Eli Lilly’s investor relations site directly. \nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on EPS and revenue\, guidance raised\nShares likely to rise\, pharmaceutical sector sentiment may improve\nDemand for Zepbound and Mounjaro continues to exceed expectations\, and the company is managing supply well enough to convert that demand into sales\n\n\nIn line with expectations\nLimited share price reaction\, attention shifts to forward guidance and pipeline commentary\nThe quarter unfolded roughly as analysts anticipated\, with no major surprises on volumes\, pricing or costs\n\n\nMiss on EPS or revenue\, or guidance cut\nShares likely to fall\, possible knock-on pressure on other weight-loss drug makers\nEither supply constraints\, pricing pressure or slower-than-expected uptake of key drugs is weighing on results\n\n\n\nWhat It Means for Your Money\nEli Lilly is a large constituent of major US stock indices\, so its share price movements feed through to index funds and exchange-traded funds that many pension schemes and workplace savings plans hold\, even for investors who have never bought the stock directly. A big swing in Eli Lilly’s share price\, in either direction\, can therefore have a small but measurable effect on diversified pension pots and index-tracking investment funds in the UK\, Europe and elsewhere. \nThe results can also move the wider healthcare and pharmaceutical sector\, since Eli Lilly’s performance in weight-loss drugs is often treated as a bellwether for rivals such as Novo Nordisk. For savers and investors holding healthcare sector funds\, a strong Eli Lilly report can lift sentiment across the sector\, while a weak one can weigh on it. For everyday consumers\, especially in the US and increasingly in Europe\, commentary on manufacturing capacity and pricing can hint at whether supply shortages or costs for drugs like Zepbound and Mounjaro are likely to ease or persist. There is no direct link between this earnings report and mortgage rates\, currency markets or broader interest rate policy\, so its effects on your money are mostly indirect\, running through pension and investment exposure rather than everyday borrowing costs. \nRelated events\n\nEli Lilly’s full-year 2026 results\, typically reported alongside or just before the Q1 2027 release\nNovo Nordisk quarterly earnings\, a key comparison point in the weight-loss drug market\nUS Consumer Price Index (CPI) release\, which can influence broader market sentiment around the same period\n\nFrequently Asked Questions\nWhat time does Eli Lilly report Q1 2027 earnings?\nThe release is expected at 7:00am ET\, which is 12:00pm in London\, though the date has not been formally confirmed by the company. \nIs the February 2\, 2027 date confirmed?\nNo. It is an estimate based on Eli Lilly’s usual pattern of reporting full-year and fourth-quarter results in early February\, and the exact date will be confirmed closer to the time. \nWhat was Eli Lilly’s most recent reported performance?\nIn its most recently confirmed quarter\, Q3 2025\, Eli Lilly reported EPS of $7.02 against a consensus estimate of $5.69\, on revenue of $17.60 billion. \nWhere can I watch the earnings call live?\nEli Lilly typically streams its earnings call live via a webcast on its investor relations website\, with a transcript posted shortly afterwards. \nWhy does Eli Lilly’s earnings report matter outside the US?\nIts weight-loss and diabetes drugs are sold and reimbursed across European health systems\, and its results often set the tone for pharmaceutical sector sentiment in London and other European markets.
URL:https://www.financecalendar.com/event/eli-lilly-lly-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
END:VCALENDAR